|
|
|
Novavax,
Inc. (NASD:NVAX) -
Investor Presentation
Dr. Rahul Singhvi
President and CEO
|
|
|
|
|
5
Day Stock chart |
|
Register to
receive updates on NVAX
(Request form opens
in new window and will not interrupt investor presentation)
|
|
About Novavax, Inc.
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses
on developing vaccines using its virus-like particle platform
technology for infectious diseases. It develops vaccines against
the H5N1 and other subtypes of avian influenza with pandemic
potential, human seasonal influenza, and Respiratory Syncytial
Virus, as well as Varicella Zoster that causes shingles. The
company has a joint venture with Cadila Pharmaceuticals Ltd. to
develop and commercialize seasonal influenza
virus-like-particle-based vaccine candidates and therapeutic
vaccine candidates against cancer, as well as adjuvants,
biogeneric products, and other diagnostic products for the
territory of India. www.novavax.com
|
|
Ludlow
BioVentures Issues $4.00 Target on Novavax, Inc. |
|
Safe Harbor Statements:
This
investor presentation may include statements that may constitute
forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Although the Company believes that the expectations
reflected in such forward-looking statements are based on
reasonable assumptions, such statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected.
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather
is for informational purposes only. Content contained herein
includes facts, views, opinions and recommendations of individuals
and organizations deemed of interest. Wall Street Newscast
("WSNC") does not guarantee the accuracy, completeness
or timeliness of, or otherwise endorse these views, opinions or
recommendations, or give investment advice. WSNC, its affiliates,
or directors, may or may not hold a position in the above security
from time to time, and investors are encourage to consider this as
a possible conflict of interest when reviewing this information.
In Compliance with SEC Rule 17B Wall Street Newscast was NOT compensated
for this investor presentation.
|
|
|
|
|
|
